Optimal designs for identifying effective doses in drug combination studies
Listen
Radio episode about this paper
Transcript
Introduction to the show: ident: Statistics. The day in statistics: methods, theory and the inference under them.
Tom: We're looking at the paper: "Optimal designs for identifying effective doses in drug combination studies".
Jane: Here's the gist of the paper. Optimal designs for identifying effective dose combinations that yield a prespecified effect are proposed to minimize the width of the confidence band of contour lines of interest.
Tom: This novel design criterion targets the precise estimation of these effective dose combinations by minimizing the Lq-norm of the variance of the prediction for the effect at those dose combinations.
Jane: Modeling Dose Combination Data The paper considers modeling the effect of two substances C and D using a nonlinear response surface model defined by Yij = η((ci, di), θ) + εij.
Tom: The regression function η is modeled additively including an interaction effect with the form η((c, d), θ) = θ0 + ηC (c, θC) + ηD(d, θD) + γηC (c, θC)ηD(d, θD).
Paper summary: Tom: So we're looking at this paper called "Optimal designs for identifying effective doses in drug combination studies". It tackles the problem of finding the best way to design experiments when you want to find dose combinations that get a specific effect from two different substances.
Jane: That sounds really practical, Tom. So, what's the main idea here? What's this paper actually claiming about designing those experiments?
Tom: The core thesis is about using an optimal design criterion to find those effective dose combinations more precisely. They want to minimize the width of the confidence band around those lines you're interested in, which basically means they're aiming for a really tight estimate of where that effect happens.
Lu: What they're doing is targeting the precise estimation of these effective dose combinations by minimizing the Lq-norm of the variance for that effect at those dose combinations. It’s about making sure you pinpoint those doses as accurately as possible, no matter what nonlinear model you use for your data.
Meng: So, if I'm running a trial and I know I need to find a certain synergy between drug C and drug D, this design method helps me narrow down where to test the doses most efficiently? How does it compare to the standard stuff?
Tom: The paper shows that this locally MED-optimal design outperforms established designs like factorial or ray designs when it comes to precision for estimating those effective dose combinations. The simulation study backs that up, showing the locally MED-optimal design has smaller root mean square error values and therefore higher precision for prediction at the set of effective dose combinations.
Jane: That's interesting because traditionally, we use those factorial or ray designs because they’re straightforward to set up, but this paper suggests they aren't always as accurate when you're dealing with nonlinear response surfaces. What kind of models are they looking at?
Lu: They model the effect of two substances C and D using a nonlinear response surface model defined by Yij equals eta parentheses c i d i, theta plus epsilon i j, where eta is modeled additively including an interaction effect with the form eta parentheses c d, theta). They even consider different functions for modeling how each substance responds individually, like linear or Emax models.
Meng: So they're not just assuming one simple way to model things; they're trying to be flexible with the underlying science, which is good for real-world drug interaction studies. But what is the actual mechanism behind this criterion? What makes it better than just picking a random design?
Paper summary: Tom: The core of the proposed criterion involves minimizing an Lq-norm of a function phi, where q is some number between one and infinity. This minimization happens over all approximate designs on the design space, subject to a constraint that the gradient of eta parentheses c zero d zero, theta) is within the range of the information matrix m(xi, theta).
Jane: That sounds mathematically intensive. So what does that constraint actually mean for someone who isn't deep in optimization? What's it telling us about choosing a design?
Lu: They use an equivalence theorem as a central tool to check if the designs they find numerically are truly optimal. It’s a way to verify the numerical solutions you get from the minimization process.
Meng: If this is about minimizing variance, what does that translate to for deployment? Does it mean fewer total experiments or just better results from the same number of experiments? I need to know if this saves time or just gives me cleaner data.
Tom: The paper suggests using this MED-optimal design allows for more precise estimation of effective concentrations compared to other designs, and it can do that even when alternative designs would require a larger number of observations to achieve the same level of precision.
Jane: So, we're talking about getting high accuracy with potentially smaller sample sizes. That ties into the 3R framework, which is important for research and animal experiments. What about uncertainty? If you're unsure about the interaction effect itself, how does this approach handle that?
Lu: They propose a robust version of the criterion called the Bayesian MED-optimal design. This accounts for uncertainty about the interaction effect by incorporating a prior distribution of that unknown parameter theta. That makes it more robust when prior knowledge about the interaction is not very informative.
Meng: A Bayesian approach sounds safer, but does it make things computationally expensive for production? How much extra overhead are we talking about when we add that prior distribution to the optimization?
Tom: The simulation study on robustness shows that both locally MED-optimal designs and the Bayesian MED design show a similar ability to estimate those contour lines for p one ten and p two thirty in a setting with an additive model. The Bayesian version performs nearly as well as the locally optimal design in that context.
Paper summary: Jane: So, it seems like they've got a solid method for handling both the precision and the uncertainty, even when things get complex with different interaction types. What's the final word on what this means practically for people doing these kinds of studies?
Tom: The paper concludes that using this MED-optimal design allows for more precise estimation of effective concentrations compared to other designs because alternative designs would need a larger number of observations to get the same precision. It also highlights that even in one dimensional cases, the confidence interval for those effective doses can be quite large in practical settings because there are various uncontrollable factors involved.
Lu: They emphasize that this approach is very flexible, allowing adaptation to any nonlinear surface model. The criterion itself is based on an Lq-norm where q is fixed beforehand. For example, they found that q equals two outperformed q equals one in their analysis of the optimal designs for various selected values of q.
Meng: So it's adaptable to different scientific models, which is good for flexibility, but we still have to pick that fixed value of q upfront. That’s a design choice we have to make before we even start the experiment.
Jane: It sounds like this method offers a way forward for making dose combination studies more efficient and reliable by focusing on minimizing the asymptotic variance of those effective dose combinations, which means less variability in how precisely you estimate the doses you need.
Tom: So, to wrap up on "Optimal designs for identifying effective doses in drug combination studies," this paper proposes a design approach that uses an Lq-norm criterion to find the best way to identify effective dose combinations within drug combination studies where two drugs interact.
Jane: And it claims this method provides higher precision than traditional methods like factorial or ray designs when estimating those effective dose combinations, and it does so with potentially fewer measurements.
Lu: The paper also suggests that this framework can handle uncertainty about the interaction effect using a Bayesian approach, making it more robust when prior information is limited.
Meng: From an engineering standpoint, the main point is that this design method gives you higher precision for your predictions and helps you understand how much data you actually need to collect.
Tom: It’s about moving beyond just picking a fixed design type and instead finding a criterion that adapts to any nonlinear surface model while aiming for the tightest possible estimate of those effective dose combinations.
Conclusion: Tom: So, we've been looking at this paper called "Optimal designs for identifying effective doses in drug combination studies" by Schürmeyer and her team, and it boils down to finding the best experimental design when you're testing two drugs together.
Jane: It’s about using a specific math rule, an Lq-norm criterion, to figure out exactly where the optimal dose combinations are so you don't waste time testing things that won't show any effect.
Tom: They show this approach beats traditional designs like factorial or ray designs when it comes to getting a tighter estimate of those effective dose combinations.
Jane: So, what does that mean for the actual science? If you use this method, are you getting a better picture of how those drugs work together than if you just run a standard experiment?
Tom: It means the precision for your predictions is higher because the design is specifically optimized to minimize the error in estimating those dose combinations.
Jane: That sounds useful for drug discovery because it helps you narrow down which combinations actually matter, even when your response surface model is complex and nonlinear.
Tom: Exactly. The paper also introduces a way to make this design more robust by using a Bayesian version that accounts for uncertainty about the interaction effect itself, which is important when you don't have perfect prior knowledge.
Jane: So, while the main point is better precision, they’ve also thought about making it safer when the underlying scientific assumptions aren't crystal clear.
Tom: Right. It’s not just a new way to run an experiment; it’s a smarter way to choose the experiment itself based on what you already know about how these substances interact.
Jane: It definitely points toward more efficient research, potentially letting us get better results with smaller sample sizes for animal studies or human trials.
Tom: It suggests that instead of sticking to old methods blindly, you can use this criterion to adapt your experimental plan to any nonlinear model you throw at it.
Jane: It’s a flexible tool for figuring out those precise dose combinations that lead to the desired effect size. Next up, we're going to look at how they actually tested this on different types of drug data.
Leonie Schürmeyer, Ludger Sandig, Jorrit Öhne, Leonie Theresa Hezler, Bernd-Wolfgang Igl, Kirsten Schorning
TU Dortmund University · Boehringer Ingelheim Pharma GmbH & Co. KG
stat.ME, stat.AP
Submitted: 2025-06-06
Updated: 2025-12-10
DOI: 10.1002/bimj.70186
License: http://creativecommons.org/licenses/by/4.0/
Importance score: 79/100
The gist: Optimal designs for identifying effective dose combinations that yield a prespecified effect are proposed to minimize the width of the confidence band of contour lines of interest.
Key concepts
- Nonlinear Response Surface Model
- This is a mathematical model used to describe how the effect of two drugs (C and D) changes based on their respective doses (c and d). The model includes terms for individual effects and an interaction term showing how the effect of one drug depends on the dose of the other, allowing for complex, non-straight-line relationships.
- Lq-norm Criterion
- This is a mathematical rule used to define what makes a design 'optimal.' The goal is to minimize this norm applied to the variance of predictions at the desired effective dose combinations. Minimizing this value directly leads to designs that provide the most precise estimates for those specific doses.
- MED-Optimal Design
- This is a specific type of optimal design derived from minimizing an Lq-norm criterion. It is designed to be highly efficient at pinpointing the effective dose combinations for a target effect size, often showing superior precision compared to standard designs like factorial or ray designs.
Terminology
Summary
Optimal designs for identifying effective dose combinations that yield a prespecified effect are proposed to minimize the width of the confidence band of contour lines of interest. p. 0 We propose a novel design criterion that targets the precise estimation of these effective dose
combinations. In particular, an optimal design minimizes the width of the confidence band of the
contour lines of interest. If nonlinear surface models are used to describe the
dose combination-response relationship, these effective dose combinations result in specific contour
lines of the fitted response model. We propose a novel design criterion that targets the precise estimation of these effective dose
combinations.Where the paper says it
Where the paper says it
Modeling Dose Combination Data
The paper considers modeling the effect of two substances C and D using a nonlinear response surface model defined by Yij = η((ci, di), θ) + εij. The regression function η is modeled additively including an interaction effect with the form η((c, d), θ) = θ0 + ηC (c, θC) + ηD(d, θD) + γηC (c, θC)ηD(d, θD). p. 2 More precisely, let ηC (· , θC ), θC ∈ ΘC ⊂ R
mC , and ηD(· , θD),
θD ∈ ΘD ⊂ R
mD be the parts of the individual regression functions describing the dose-specific effect of the substances
C and D, respectively. Then we define the corresponding regression function for the dose combination in an additive
manner including an interaction effect with
η((c, d), θ) = θ0 + ηC (c, θC ) + ηD(d, θD) + γηC (c, θC )ηD(d, θD), (2)
where the parameter θ = (θ0, θC , θD, γ) consists of the individual parameters θC and θD of the regression functions
ηC and ηD, a joint placebo parameter θ0 and the parameter γ ∈ R that describes potential dose-independent interaction
effects between the two substances. There are various approaches for modeling the combination of two substances differing by the choice of the regression
function η. One natural choice for the regression function η includes the regression functions used to describe the
dose-specific effect of the individual substances. A PREPRINT - DECEMBER 12, 2025
Another natural choice for the regression function η is included in the response surface model called Greco model. According to Liou et al.Where the paper says it
Where the paper says it
Where the paper says it
Where the gains come from
The core of the proposed criterion is to minimize a Lq-norm of the function φ, q ∈ [1, ∞) of the function φ defined in (4). This minimization is performed over all approximate designs ξ on the design space Z with a constraint that the gradient of η((c0, d0), θ) is in the range of the information matrix M(ξ, θ). p. 3 Here, D
→ denotes convergence in distribution and the function φ is defined by
φ
(c0, d0), ξ, θ
=
∂
∂θ η
(c0, d0), θ
T
M−(ξ, θ)
∂
∂θ η
(c0, d0), θ
, (4)
where M(ξ, θ) = Z
Z
∂
∂θ η((c, d), θ)
∂
∂θ η((c, d), θ)
T
dξ((c, d)) (5)
is the information matrix corresponding to the design ξ, and ∂
∂θ η((c, d), θ) is the gradient of η with respect to the
parameter θ ∈ R
m. The matrix M−(ξ, θ) is the generalized inverse of the information matrix, whereby the design ξ
has to satisfy ∂
∂θ η((c0, d0), θ) ∈ range(M(ξ, θ)). , MEDpk
and the parameter θ, if it satisfies ∂
∂θ η((c, d), θ) ∈ range(M(ξ
∗
, θ))
for all (c, d) ∈
Sk
i=1 MEDpi
and if it minimizes the function ϕMEDq
(ξ, θ) in (10) over the space of all approximate
designs ξ on Z with ∂
∂θ η((c, d), θ) ∈ range(M(ξ, θ) for all (c, d) ∈
Sk
i=1 MEDpi
. A central tool of optimal design theory is the equivalence theorem, which is frequently used to check the optimality
of candidate designs determined numerically.Where the paper says it
Where the paper says it
Pruning redundant reasoning tokens
The performance comparison in a case study demonstrates that the locally MED-optimal design outperforms established designs such as factorial and ray designs in terms of precision when estimating effective dose combinations. The simulation study confirms this, showing that the locally MED-optimal design exhibits the smallest RMSE values and therefore the highest precision for prediction at the set of effective dose combinations. p. 4 3 Optimal design theory for identifying sets of effective doses in drug combination studies
Dose combination studies aim to identify the dose combinations (c, d) ∈ MEDp for prespecified values for p%. Using
(6) the pointwise confidence band of the prediction of effects at the dose combinations contained in the MEDp is given
by
η((c, d),
ˆθ) ± z1−α/2
σˆ
√
N
φ
1/2
((c, d), ξ, ˆθ)
(c, d) ∈ MEDp
, (9)
where the asymptotic variance function φ((c, d), ξ, ˆθ) is defined in (4).Where the paper says it
How the training signal is built
The robustness analysis investigates how different designs perform across various scenarios involving different interaction types and response surface models. The Bayesian MED-optimal design is proposed as a robust version of the criterion that accounts for uncertainty about the interaction effect by incorporating a prior distribution of the unknown parameter θ. p. 6 More precisely, let
π be a prior distribution of the unknown parameter θ ∈ Θ, then a design ξ
∗
is called Bayesian MEDq-optimal, if it
minimizes the function
ψ(ξ) = Z
Θ
ϕMEDq
(ξ, θ)dπ(θ) (15)
for all possible designs ξ ∈ Ξ, where Ξ denotes the set of all possible approximate designs on the design space Z. For the Bayesian version of the MEDq-criterion, analogous versions of the equivalence theorem in Theorem 3 and
efficiency bounds such as in Corollary 6 can be derived.Where the paper says it
The paper concludes that using the MED-optimal design allows for more precise estimation of effective concentrations compared to other designs, as alternative designs would require a larger number of observations to achieve the same level of precision. The proposed approach is flexible, allowing adaptation to any nonlinear surface model and focusing on identifying multivariate effective dose combinations that lead to p% of the maximal effect. p. 4 Instead, several different
dose combinations (c, d) ∈ Z yield the same effect, resulting in contour lines on the surface model. Extending the
one-dimensional definition of the EDp in (7), the set of multivariate effective doses for achieving p% (0 < p < 100) of
the maximum effect in the considered design range Z = [0, cmax] × [0, dmax] can be defined by
MEDp(θ) =
(c, d) ∈ Z
η((c, d), θ) − min(c0,d0)∈Z η((c0, d0), θ)
Rmax
=
p
100
, (8)
where the Rmax denotes the maximal effect of the response in the design space and is given by
Rmax = max
(c,d)∈Z
η((c, d), θ) − min
(c,d)∈Z
η((c, d), θ). The theoretical comparison focuses on efficiencies of the different design approaches, while the practical
aspect is explored through simulation studies. We compare conventional designs, such as factorial and ray designs, against the newly derived MEDq-optimal designs
in terms of their precision in estimating effective dose combinations. In Section 3, we will introduce the optimal design theory in the context
of drug-combination studies aiming to estimate the effective dose combinations accurately. More precisely, the new
developed optimal design criterion minimizes the Lq-norm of the variance of the prediction for the effect at the effective
dose-combinations. In Section 3, we will introduce the optimal design theory in the context
of drug-combination studies aiming to estimate the effective dose combinations accurately. More precisely, the new
developed optimal design criterion minimizes the Lq-norm of the variance of the prediction for the effect at the effective
dose-combinations. Therefore, we consider robust designs for various values of the interaction effect. Additionally, we
investigate the capability of the resulting designs to provide precise estimates of the effective doses and assess their
performance under these varying conditions. More precisely, the confidence interval for the level (1 − α) is
given by
η
(c0, d0),
ˆθ
± z1−α/2
σˆ
√
N
φ
1/2
(c0, d0),
ˆθ
, (6)
where σˆ and ˆθ denote the maximum likelihood estimates of the parameters σ and θ, z1−α/2 denotes the (1 − α/2)-
quantile of the standard normal distribution and the function φ is given in (4). 1 Effective doses in dose combination studies
In classical dose-response experiments where the effect of one substance is investigated, special interest lies on effective
doses (ED) that result in a certain percentage of the maximal effect. 3 Optimal design theory for identifying sets of effective doses in drug combination studies
Dose combination studies aim to identify the dose combinations (c, d) ∈ MEDp for prespecified values for p%. Using
(6) the pointwise confidence band of the prediction of effects at the dose combinations contained in the MEDp is given
by
η((c, d),
ˆθ) ± z1−α/2
σˆ
√
N
φ
1/2
((c, d), ξ, ˆθ)
(c, d) ∈ MEDp
, (9)
where the asymptotic variance function φ((c, d), ξ, ˆθ) is defined in (4). 3 Optimal design theory for identifying sets of effective doses in drug combination studies
Dose combination studies aim to identify the dose combinations (c, d) ∈ MEDp for prespecified values for p%. Using
(6) the pointwise confidence band of the prediction of effects at the dose combinations contained in the MEDp is given
by
η((c, d),
ˆθ) ± z1−α/2
σˆ
√
N
φ
1/2
((c, d), ξ, ˆθ)
(c, d) ∈ MEDp
, (9)
where the asymptotic variance function φ((c, d), ξ, ˆθ) is defined in (4).Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
The paper is supported by funding from the Research Training Group “Biostatistical Methods for High-Dimensional Data in Toxicology” (RTG 2624, Project P5) funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation - Project Number 427806116). The code supporting the findings is openly available in Zenodo at [Schürmeyer et al. p. 8 The subsequent simulations and analyses
were performed in R [R Core Team, 2024]. Our code and the computed designs can be found in Zenodo at [Schürmeyer
et al. Drug combination
studies are becoming increasingly important as they investigate potential interaction effects rather
than the individual impacts of the drugs. In this situation, identifying effective dose combinations that
yield a prespecified effect is of special interest. Our code and the computed designs can be found in Zenodo at [Schürmeyer
et al. 1 Efficiency-based comparison for the case study data
It is well established that the selection of dose combinations has a direct impact on the precision of estimation. Here, we also present two specific approaches of surface modeling
as commonly used in drug combination studies. In Section 3, we will introduce the optimal design theory in the context
of drug-combination studies aiming to estimate the effective dose combinations accurately. In Section 4, the statement of the theorem is used to check the optimality of the numerically
determined designs. The proof of Theorem 3 can be found in the Supplementary Material. For the comparison, we restrict ourselves to the
L2-norm in the criterion resulting in locally MED2-optimal designs to which we refer as MED-optimal designs for the
sake of brevity. The considered factorial or ray designs motivated from practical aspects are visualized in the Appendix
Figure 9. By definition, the highest efficiencies across the different criteria are
achieved by their corresponding optimal designs. For a precise estimation of effective doses at the 10% and 50% levels,
the D-optimal design demonstrates the next highest efficiency, followed by the locally MED-optimal design for the
10 By definition, the highest efficiencies across the different criteria are
achieved by their corresponding optimal designs. For a precise estimation of effective doses at the 10% and 50% levels,
the D-optimal design demonstrates the next highest efficiency, followed by the locally MED-optimal design for the
10 Finally, we examine the robustness of the developed design approach. In drug combination studies, monotherapies are
often known in advance, while the interaction effect may not be clearly defined before conducting the drug combination
experiment. Finally, we examine the robustness of the developed design approach. In drug combination studies, monotherapies are
often known in advance, while the interaction effect may not be clearly defined before conducting the drug combination
experiment. Therefore, a design in drug combination studies that
facilitates precise estimation of these effective dose combinations leading to a prespecified effect level of interest is
needed. This paper aims to construct efficient designs for achieving a target effect size using nonlinear surface models. [2019]
consider nonlinear surface models to describe the dose combination response relationship across the whole design space
but mainly address the design problem by using the classical D-optimality criterion instead of explicitly targeting the
precise estimation of effective dose combinations. To address this gap, we propose a new and flexible design criterion
that aims to accurately estimate effective dose combinations in drug combination studies. The subsequent simulations and analyses
were performed in R [R Core Team, 2024]. Our code and the computed designs can be found in Zenodo at [Schürmeyer
et al. More precisely, the confidence interval for the level (1 − α) is
given by
η
(c0, d0),
ˆθ
± z1−α/2
σˆ
√
N
φ
1/2
(c0, d0),
ˆθ
, (6)
where σˆ and ˆθ denote the maximum likelihood estimates of the parameters σ and θ, z1−α/2 denotes the (1 − α/2)-
quantile of the standard normal distribution and the function φ is given in (4). 1 Effective doses in dose combination studies
In classical dose-response experiments where the effect of one substance is investigated, special interest lies on effective
doses (ED) that result in a certain percentage of the maximal effect.Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
--- Page 1 ---
OPTIMAL DESIGNS FOR IDENTIFYING EFFECTIVE DOSES IN DRUG COMBINATION STUDIES
Leonie Schürmeyer
Department of Statistics
TU Dortmund University
Dortmund, 44227, Germany. Ludger Sandig
Department of Statistics
TU Dortmund University
Dortmund, 44227, Germany. Jorrit Kühne
Department of Statistics
TU Dortmund University
Dortmund, 44227, Germany. Leonie Theresa Hezler
Global Experimental Medicine, Data and Analytics
Boehringer Ingelheim Pharma GmbH & Co. KG
Biberach an der Riß, 88397, Germany. Bernd-Wolfgang Igl
Global Experimental Medicine, Data and Analytics
Boehringer Ingelheim Pharma GmbH & Co. KG
Biberach an der Riß, 88397, Germany. Kirsten Schorning
Department of Statistics
TU Dortmund University
Dortmund, 44227, Germany. December 12, 2025. p. 0 tu-dortmund. de
December 12, 2025
ABSTRACT
We consider the optimal design problem for identifying effective dose combinations within drug combination studies where the effect of the combination of two drugs is investigated.Where the paper says it
--- Page 2 ---
A PREPRINT - DECEMBER 12, 2025
A PREPRINT - DECEMBER 12, 2025
A PREPRINT - DECEMBER 12, 2025
The paper considers the optimal design problem for identifying effective dose combinations within drug combination studies where the effect of the combination of two drugs is investigated. Identifying effective dose combinations that yield a prespecified effect is of special interest. p. 0 Drug combination
studies are becoming increasingly important as they investigate potential interaction effects rather
than the individual impacts of the drugs. In this situation, identifying effective dose combinations that
yield a prespecified effect is of special interest.Where the paper says it
The paper aims to construct efficient designs for achieving a target effect size using nonlinear surface models. The proposed optimal design criterion minimizes the Lq-norm of the variance of the prediction for the effect at the effective dose combinations. p. 1 More precisely, the new
developed optimal design criterion minimizes the Lq-norm of the variance of the prediction for the effect at the effective
dose-combinations. Note that a similar approach is proposed by Miller et al.Where the paper says it
The performance of this optimal design is illustrated in different examples modeling dose combination data by various nonlinear surface models. It is demonstrated that the proposed optimal design yields a more precise estimation of the effective dose combinations than ray or factorial designs. p. 0 The performance of the optimal design is illustrated in different
examples modeling dose combination data by various nonlinear surface models. It is demonstrated
that the proposed optimal design for identifying effective dose combinations yields a more precise
estimation of the effective dose combinations than ray or factorial designs, which are commonly used
in practice.Where the paper says it
The paper compares conventional designs against newly derived MEDq-optimal designs in terms of their precision in estimating effective dose combinations. The comparison is based on the L2-norm criterion resulting in locally MED2-optimal designs referred to as MED-optimal designs. p. 8 We compare conventional designs, such as factorial and ray designs, against the newly derived MEDq-optimal designs
in terms of their precision in estimating effective dose combinations. For the comparison, we restrict ourselves to the
L2-norm in the criterion resulting in locally MED2-optimal designs to which we refer as MED-optimal designs for the
sake of brevity.Where the paper says it
The simulation study shows that the locally MED(10, 50)-optimal design outperforms all other designs, especially the traditionally used factorial design and both ray designs. The locally MED-optimal design shows the smallest RMSE-values and therefore the highest precision for prediction at the set of effective dose combinations. p. 4 3 Optimal design theory for identifying sets of effective doses in drug combination studies
Dose combination studies aim to identify the dose combinations (c, d) ∈ MEDp for prespecified values for p%. Using
(6) the pointwise confidence band of the prediction of effects at the dose combinations contained in the MEDp is given
by
η((c, d),
ˆθ) ± z1−α/2
σˆ
√
N
φ
1/2
((c, d), ξ, ˆθ)
(c, d) ∈ MEDp
, (9)
where the asymptotic variance function φ((c, d), ξ, ˆθ) is defined in (4).Where the paper says it
The robustness analysis demonstrates that both locally MED-optimal designs and the Bayesian MED design show a similar ability to estimate the contour lines for p1 = 10 and p2 = 30 in a setting with an additive model. The Bayesian MED-optimal design demonstrates excellent performance in this context, nearly on par with the locally optimal design. p. 9 By definition, the highest efficiencies across the different criteria are
achieved by their corresponding optimal designs. For a precise estimation of effective doses at the 10% and 50% levels,
the D-optimal design demonstrates the next highest efficiency, followed by the locally MED-optimal design for the
10Where the paper says it
Green — the paper says it, and the page is printed. Red — no passage carries it, so treat that sentence as unverified. The same check runs on your own text: check a summary against its source, $5.
Improvements for AI systems
-
Precise estimation of effective dose combinations in drug combination studies can be achieved by using a novel design criterion that
minimizes the width of the confidence band of the contour lines of interest.
-
The improved AI system can construct locally MEDq-optimal designs, which are defined as those that
minimize the Lq-norm of the variance of the prediction for the effect at effective dose combinations
by minimizing a function called phiMEDq. -
The AI can utilize equivalence theorems to check the optimality of candidate designs, which allows for
reduction of infinite dimensional optimization problems arising in optimal design theory to finite dimensional ones.
-
The system can be adapted to any nonlinear surface model, including
nonmonotonic regression functions for the individual drugs under consideration,
making it flexible for various dose combination response relationships. -
Robustness analysis can be enhanced by using a Bayesian MEDq-optimal design, which accounts for uncertainty about the interaction effect by incorporating a prior distribution of the unknown parameter theta.
Abstract
We consider the optimal design problem for identifying effective dose combinations within drug combination studies where the effect of the combination of two drugs is investigated. Drug combination studies are becoming increasingly important as they investigate potential interaction effects rather than the individual impacts of the drugs. In this situation, identifying effective dose combinations that yield a prespecified effect is of special interest. If nonlinear surface models are used to describe the dose combination-response relationship, these effective dose combinations result in specific contour lines of the fitted response model. We propose a novel design criterion that targets the precise estimation of these effective dose combinations. In particular, an optimal design minimizes the width of the confidence band of the contour lines of interest. Optimal design theory is developed for this problem, including equivalence theorems and efficiency bounds. The performance of the optimal design is illustrated in different examples modeling dose combination data by various nonlinear surface models. It is demonstrated that the proposed optimal design for identifying effective dose combinations yields a more precise estimation of the effective dose combinations than ray or factorial designs, which are commonly used in practice. This particularly holds true for a case study motivated by data from an oncological dose combination study.
Related papers
- Learning Robust Treatment Rules for Censored Data
- Neural Estimation of Summary Statistics for Simulation-Based Inference with Non-Asymptotic Guarantees
- Spectral divide-and-conquer MCMC for long stationary time series
- Improving the Efficiency of Subgroup Analysis in Randomized Controlled Trials with TMLE
- Personalized Federated Vector Autoregression with Personalization Diversity
- Doubly Robust and Efficient Calibration of Prediction Sets for Right-Censored Time-to-Event Outcomes